CR20220367A - Célula cho que expresa heterodímeros il-15 - Google Patents

Célula cho que expresa heterodímeros il-15

Info

Publication number
CR20220367A
CR20220367A CR20220367A CR20220367A CR20220367A CR 20220367 A CR20220367 A CR 20220367A CR 20220367 A CR20220367 A CR 20220367A CR 20220367 A CR20220367 A CR 20220367A CR 20220367 A CR20220367 A CR 20220367A
Authority
CR
Costa Rica
Prior art keywords
cho cell
heterodimers
cell expressing
heterodimer
producing
Prior art date
Application number
CR20220367A
Other languages
English (en)
Inventor
Justyna Jozefczuk
Urs Ulrich Lohrig
Richard Gabriel
Thomas Jostock
Alexandre Aurélien Pons
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20220367A publication Critical patent/CR20220367A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al heterodímero de IL–15/IL–15Ra producido en una línea celular CHO, y método de producción del heterodímero y método de tratamiento utilizando el heterodímero.
CR20220367A 2020-02-05 2021-01-29 Célula cho que expresa heterodímeros il-15 CR20220367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05
PCT/IB2021/050730 WO2021156720A1 (en) 2020-02-05 2021-01-29 Cho cell expressing il-15 heterodimers

Publications (1)

Publication Number Publication Date
CR20220367A true CR20220367A (es) 2022-08-30

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220367A CR20220367A (es) 2020-02-05 2021-01-29 Célula cho que expresa heterodímeros il-15

Country Status (22)

Country Link
US (1) US20210244821A1 (es)
EP (1) EP4100425A1 (es)
JP (2) JP2022522566A (es)
KR (1) KR20220137651A (es)
CN (1) CN115023436A (es)
AR (1) AR121261A1 (es)
AU (1) AU2021215893A1 (es)
BR (1) BR112022014493A2 (es)
CA (1) CA3168469A1 (es)
CL (2) CL2022002094A1 (es)
CO (1) CO2022010860A2 (es)
CR (1) CR20220367A (es)
DO (1) DOP2022000156A (es)
EC (1) ECSP22060286A (es)
IL (1) IL295278A (es)
JO (1) JOP20220174A1 (es)
MX (1) MX2022009611A (es)
PE (1) PE20221509A1 (es)
PH (1) PH12022552029A1 (es)
TW (1) TWI893058B (es)
UY (1) UY39062A (es)
WO (1) WO2021156720A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
EP4232069A1 (en) 2020-10-26 2023-08-30 Cytune Pharma Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma
TW202434276A (zh) 2022-11-04 2024-09-01 瑞士商諾華公司 Ｎｋｇ２ｄ融合蛋白癌症療法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
MX357691B (es) * 2006-01-13 2018-07-19 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
EP2326531B2 (en) 2008-08-22 2021-01-13 Magna Seating Inc. Disc recliner with reduced backlash
WO2010072676A1 (en) * 2008-12-22 2010-07-01 Lek Pharmaceuticals D.D. Mammalian expression vector
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP3851459B1 (en) * 2010-09-21 2024-05-01 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
WO2012094627A2 (en) * 2011-01-06 2012-07-12 The Johns Hopkins University Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells
EP2911684B1 (en) * 2012-10-24 2019-06-19 Novartis Ag Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
MX368664B (es) * 2014-04-29 2019-10-10 Novartis Ag Células novedosas de vertebrados y métodos para la expresión recombinante de un polipéptido de interés.
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
SI3235830T1 (sl) * 2014-12-19 2020-12-31 Jiangsu Hengrui Medicine Co., Ltd. Proteinski kompleks interlevkina 15 in njegove uporabe
EP3390643B8 (en) * 2015-12-18 2023-08-02 OncoSec Medical Incorporated Plasmid constructs for heterologous protein expression and methods of use
JP7200104B2 (ja) * 2016-08-01 2023-01-06 ヴァイロジン バイオテック カナダ リミテッド 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター
PE20240950A1 (es) * 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
EP3529263B1 (en) * 2016-10-21 2025-08-06 Altor BioScience Corporation Multimeric il-15-based molecules
JP2020505350A (ja) * 2017-01-20 2020-02-20 ノバルティス アーゲー 癌の治療のための組合せ療法
JP2021512104A (ja) * 2018-02-02 2021-05-13 ノバルティス アーゲー 癌の治療のためのＳＴＩＮＧアゴニスト及びＩＬ−１５／ＩＬ１５−Ｒａの組合せ
BR112020015202A2 (pt) * 2018-03-01 2020-12-29 Glycotope Gmbh Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15

Also Published As

Publication number Publication date
CN115023436A (zh) 2022-09-06
CL2023002447A1 (es) 2024-03-15
JP2023145622A (ja) 2023-10-11
PE20221509A1 (es) 2022-10-04
CL2022002094A1 (es) 2023-03-10
TWI893058B (zh) 2025-08-11
US20210244821A1 (en) 2021-08-12
CA3168469A1 (en) 2021-08-12
ECSP22060286A (es) 2022-09-30
AR121261A1 (es) 2022-05-04
CO2022010860A2 (es) 2022-08-19
TW202142558A (zh) 2021-11-16
JOP20220174A1 (ar) 2023-01-30
EP4100425A1 (en) 2022-12-14
DOP2022000156A (es) 2022-10-16
UY39062A (es) 2021-09-30
BR112022014493A2 (pt) 2022-09-20
PH12022552029A1 (en) 2023-11-20
MX2022009611A (es) 2022-11-07
JP2022522566A (ja) 2022-04-20
WO2021156720A1 (en) 2021-08-12
KR20220137651A (ko) 2022-10-12
AU2021215893A1 (en) 2022-08-25
IL295278A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
CR20220367A (es) Célula cho que expresa heterodímeros il-15
CL2015002469A1 (es) Anticuerpos dirigidos contra il-33 y sus usos
MX2021002247A (es) Metodo y aparato de transmision de datos y terminal.
EP2884043A3 (en) System and method for performing downhole stimulation operations
MX375669B (es) Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos.
DE602004027736D1 (de) System zur erzeugung von schockwellen
EA202091989A1 (ru) Способы лечения язвенного колита
GB2530428A (en) Optical computing device having a redundant light source and optical train
UY36435A (es) Supresión del arni parental del gen kruppel para controlar plagas de coleópteros
PE20171734A1 (es) Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico
MX2024006949A (es) Combinaciones
EA202191565A1 (ru) Способ получения циклического динуклеотида
EP4625409A4 (en) METHOD AND APPARATUS FOR VOICE INTERACTION, AND ASSOCIATED DEVICE
EP4299509A4 (en) HYDROGEN PRODUCTION DEVICE
MX2017002477A (es) Sistema de generacion de medios y metodos para llevarlo a cabo.
Nizamutdinov et al. Economic development and migration
EP4415525C0 (fr) Dispositif de production de denrées végétales en terre hors sol
PL442396A1 (pl) Turbina pionowa napędzana siłą wiatru
TR201902318U5 (tr) Akilli kask si̇nyali̇zasyon yapilanmasi
EP4317055A4 (en) HYDROGEN PRODUCTION DEVICE
EP4611343A4 (en) METHOD AND APPARATUS FOR TRANSMITTING A MESSAGE, AND DEVICE
JP1709015S (ja) 置物
TR202107194U5 (tr) Geli̇şti̇ri̇lmi̇ş di̇şli̇ vi̇da bağlantisi
EP4561187A4 (en) POWER MARGIN REPORTING METHOD BASED ON MULTI-PANEL TRANSMISSION, AND APPARATUS
Beamish Slavery's Borderland: Freedom and Bondage along the Ohio River